{
    "clinical_study": {
        "@rank": "67122", 
        "arm_group": [
            {
                "arm_group_label": "Primed Mesenchymal Stem Cells", 
                "arm_group_type": "Active Comparator", 
                "description": "Mesenchymal Stem Cells primed prior to injection to have a more effective anti inflammatory effect for Multiple Sclerosis Patients who do not respond to conventional treatments"
            }, 
            {
                "arm_group_label": "unprimed  autologous MSCs", 
                "arm_group_type": "Active Comparator", 
                "description": "Mesenchymal Stem Cells injected to Multiple Sclerosis enrolled patients"
            }
        ], 
        "brief_summary": {
            "textblock": "1. Expanding and priming Bone Marrow (BM)- Mesenchymal Stem Cells (MSCs) to a clinical\n           scale according to Good Laboratory Practice using xenogenic free media instead of the\n           previously used FCS.\n\n        2. Assessing the safety of injecting autologous BM-MSCs to Multiple Sclerosis (MS)patients\n           who fail to respond to conventional treatment.\n\n        3. Assessing the therapeutic benefits on the participants in the trial as per established\n           methods."
        }, 
        "brief_title": "Safety and Efficacy Study of Autologus Bone Marrow Mesenchymal Stem Cells in Multiple Sclerosis", 
        "condition": "Multiple Sclerosis", 
        "condition_browse": {
            "mesh_term": [
                "Multiple Sclerosis", 
                "Sclerosis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  A clinical diagnosis of definite MS according to the revised McDonald Criteria.\n\n          -  Expanded Disability Status Scale (EDSS) \u2264 6\n\n          -  Failure of standard medical therapy\n\n          -  Disease duration of at least three years prior to enrollment.\n\n        Exclusion Criteria:\n\n          -  Pregnant and lactating women\n\n          -  Previous treatment with immunosuppressive agents in the last 12 months prior to\n             enrollment\n\n          -  Recent MS relapse in the month prior to enrollment\n\n          -  Treatment with oral or parenteral steroids for any cause in the month prior to\n             enrollment\n\n          -  Significant systemic medical disorders including cardiac, renal, hepatic,\n             hematologic, immunologic or endocrine disorders\n\n          -  Previous treatment with interferons or glatiramer acetate in the 3 months prior to\n             enrollment\n\n          -  Any contra-indication for magnetic resonance imaging (MRI) or gadolinium    contrast.\n\n          -  Positive serology for HIV, Hepatitis B or Hepatitis C\n\n          -  Any history of malignancy or exposure to radiation at any time prior to enrollment\n\n          -  Any contra-indication to lumbar puncture\n\n          -  Severe cognitive impairment that would interfere with the patient's ability to\n             understand and sign the informed consent."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 24, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01895439", 
            "org_study_id": "MSUJCTC"
        }, 
        "intervention": {
            "arm_group_label": [
                "Primed Mesenchymal Stem Cells", 
                "unprimed  autologous MSCs"
            ], 
            "intervention_name": "Autologous Mesenchymal Stem Cells", 
            "intervention_type": "Biological"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Bone marrow derived Mesenchymal Stem Cells", 
            "Multiple Sclerosis", 
            "Oligodendrocytes", 
            "Neuroimmunology", 
            "Autoimmune disease"
        ], 
        "lastchanged_date": "July 3, 2013", 
        "location": {
            "contact": {
                "email": "ftmjamali@gmail.com", 
                "last_name": "Fatima Jamali, MSc.", 
                "phone": "009625355000", 
                "phone_ext": "23960"
            }, 
            "contact_backup": {
                "email": "d.hattab@ju.edu.jo", 
                "last_name": "Dana Hattab, MSc.", 
                "phone": "009625355000", 
                "phone_ext": "23960"
            }, 
            "facility": {
                "address": {
                    "city": "Amman", 
                    "country": "Jordan", 
                    "zip": "11942"
                }, 
                "name": "Cell Therapy Center, Jordan University Hospital"
            }, 
            "investigator": [
                {
                    "last_name": "Osama H Ababneh, MD.", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Yacoub Bahou, MD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Muawyah Bdour, MD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Nusayba Ryalat, MD.", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Imad Tarawneh, MD", 
                    "role": "Principal Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Jordan"
        }, 
        "number_of_arms": "2", 
        "official_title": "Phase II Study: Use of Autologus Mesenchymal Stem Cells in Multiple Sclerosis Patients Who do Not Respond to Conventional Treatment", 
        "overall_contact": {
            "email": "ftmjamali@gmail.com", 
            "last_name": "Fatima Abbas Jamali, MSc.", 
            "phone": "009625355000", 
            "phone_ext": "23960"
        }, 
        "overall_contact_backup": {
            "email": "d.hattab@ju.edu.jo", 
            "last_name": "Dana Majed Hattab, MSc.", 
            "phone": "009625355000", 
            "phone_ext": "23960"
        }, 
        "overall_official": [
            {
                "affiliation": "Cell Therapy Center", 
                "last_name": "Abdallah Awidi, MD.", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "Jordan University Hospital", 
                "last_name": "Said Dahbour, MD.", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Jordan: Ethical Committee", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Assessing the safety of autologous Mesenchymal Stem Cells injection by recording the number of patients with any relevant side effects observed", 
            "safety_issue": "Yes", 
            "time_frame": "18 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01895439"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Jordan", 
            "investigator_full_name": "Fatima Jamali", 
            "investigator_title": "Researcher", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "For every patient tests would be performed at baseline and repeated at 3, 6, and 18 months post-injection", 
            "measure": "Assessing the therapeutic benefits of the injected Autologous Mesenchymal Stem Cells by Magnetic Resonance Imaging (MRI) and ophthalmological tests.", 
            "safety_issue": "No", 
            "time_frame": "18 months"
        }, 
        "source": "University of Jordan", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Jordan", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 2013"
    }
}